Cytolytic Virus Activation Therapy for Epstein-Barr Virus–Driven Tumors

Abstract

Our results in the initial CLVA-treated patients indicate that the therapy had a biological effect and was well tolerated with only moderate transient toxicity. This new virus-specific therapy could open a generic approach for treatment of multiple EBV-associated malignancies.